Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Angina - stable - How up-to-date is this topic?
Changes

Version 1.2, revision planned in 2013.

Last revised in September 2009

October 2010 — minor update. Text amended to include advice about flying for people with angina, based on the British Heart Foundation Factfile, Fitness to fly for passengers with cardiovascular disease, which is derived from the British Cardiovascular Society Working Group's expert guidance [BHF, 2010]. Issued in October 2010.

January 2010 — minor update. Ivabradine is now licensed for use in combination with a beta-blocker in people who are inadequately controlled with an optimal beta-blocker dose and whose heart rate is greater than 60 beats per minute. The recommendations regarding people with poor control on existing treatment have been updated. Issued in January 2010.

April to September 2009 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.

The anti-anginal drug ivabradine has been added as an alternative to a calcium-channel blocker, a nitrate, or nicorandil in people who cannot take a beta-blocker.

© NHS Institute for Innovation and Improvement